[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 457,458,048
  • Shares Outstanding, K 1,766,793
  • Annual Sales, $ 61,160 M
  • Annual Income, $ 4,226 M
  • EBIT $ 16,870 M
  • EBITDA $ 25,856 M
  • 60-Month Beta 0.30
  • Price/Sales 7.23
  • Price/Cash Flow 16.53
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 25.23% (+0.54%)
  • Historical Volatility 24.81%
  • IV Percentile 28%
  • IV Rank 40.23%
  • IV High 35.30% on 04/27/26
  • IV Low 18.46% on 08/22/25
  • Expected Move (DTE 1) 3.85 (1.45%)
  • Put/Call Vol Ratio 0.59
  • Today's Volume 18,107
  • Volume Avg (30-Day) 17,346
  • Put/Call OI Ratio 0.79
  • Today's Open Interest 284,505
  • Open Int (30-Day) 281,043
  • Expected Range 262.12 to 269.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $3.87
  • Number of Estimates 5
  • High Estimate $3.95
  • Low Estimate $3.84
  • Prior Year $1.86
  • Growth Rate Est. (year over year) +108.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
241.20 +10.27%
on 08/06/26
267.47 -0.56%
on 07/29/26
+11.48 (+4.51%)
since 07/17/26
3-Month
208.99 +27.26%
on 06/02/26
267.47 -0.56%
on 07/29/26
+52.21 (+24.42%)
since 05/19/26
52-Week
190.75 +39.43%
on 04/29/26
267.47 -0.56%
on 07/29/26
+59.78 (+28.99%)
since 08/19/25

Most Recent Stories

More News
AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support

NORTH CHICAGO, Ill. , Aug. 18, 2026 /PRNewswire/ --  AbbVie (NYSE: ABBV) today announced 34 students living with inflammatory conditions across dermatology, gastroenterology and rheumatology...

ABBV : 265.97 (+2.72%)
2 Reasons to Like ABBV and 1 to Stay Skeptical

2 Reasons to Like ABBV and 1 to Stay Skeptical

ABBV : 265.97 (+2.72%)
Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices

IRVINE, Calif. , Aug. 11, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, today announced updates to Allergan Partner Privileges ® (APP), its customer portfolio loyalty program,...

ABBV : 265.97 (+2.72%)
MarketBeat Week in Review – 08/03 - 08/07

A weekly roundup of MarketBeat analysis covering earnings from AbbVie, AMD, Palantir, Meta, Reddit, SpaceX and others, plus upcoming CPI and PPI inflation data.

META : 546.03 (+0.43%)
ULTA : 527.85 (+2.15%)
SNDK : 1,568.87 (-3.50%)
RDDT : 151.71 (-4.13%)
RKLB : 75.84 (-4.19%)
ADM : 80.76 (-1.43%)
ABBV : 265.97 (+2.72%)
INBK : 28.64 (-2.52%)
BOOT : 169.17 (+7.01%)
MCD : 267.45 (+0.17%)
SPCX : 139.65 (-2.57%)
AMD : 466.42 (-3.71%)
The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call

The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call

ABBV : 265.97 (+2.72%)
3 Cash-Producing Stocks for Long-Term Investors

3 Cash-Producing Stocks for Long-Term Investors

CPAY : 407.08 (+0.06%)
ABBV : 265.97 (+2.72%)
CRGY : 13.43 (+3.71%)
Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

IRVINE, Calif. , Aug. 4, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental...

ABBV : 265.97 (+2.72%)
The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure

As the NASDAQ-100 corrects amid an AI CapEx-driven tech sell-off, sectors like healthcare and financials are rallying, boosting diversified value ETFs like the Schwab U.S. Large-Cap Value ETF (SCHV).

JPM : 357.26 (-1.65%)
XOM : 164.77 (-0.48%)
JNJ : 273.41 (+0.85%)
SCHV : 35.04 (-0.11%)
MU : 937.10 (-0.39%)
BRK-B : N/A (N/A)
ABBV : 265.97 (+2.72%)
WMT : 114.30 (-0.78%)
What Are Wall Street Analysts' Target Price for AbbVie Stock?

Despite AbbVie’s outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

XLV : 175.68 (+3.51%)
$SPX : 7,707.98 (+0.21%)
ABBV : 265.97 (+2.72%)
AbbVie Quietly Solved Its Biggest Problem—Now What?

AbbVie posted strong Q2 revenue and EPS growth, and despite a post-earnings dip tied to the Apogee Therapeutics deal, analysts and dividend strength support shares reaching $300.

ABBV : 265.97 (+2.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 276.19
2nd Resistance Point 271.58
1st Resistance Point 268.77
Last Price 265.97
1st Support Level 261.36
2nd Support Level 256.75
3rd Support Level 253.94

See More

52-Week High 267.47
Last Price 265.97
Fibonacci 61.8% 238.16
Fibonacci 50% 229.11
Fibonacci 38.2% 220.06
52-Week Low 190.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.